BACKGROUND: The mechanisms of atherosclerotic plaque rupture are poorly understood. Urokinase-type plasminogen activator (uPA) is expressed at elevated levels by macrophages in advanced human plaques. Patients with evidence of increased plasminogen activation have an elevated risk of major cardiovascular events. We used atherosclerotic mice to test the hypothesis that increased macrophage uPA expression in advanced plaques would cause histological features similar to those in ruptured human plaques. METHODS AND RESULTS: Bone marrow from transgenic mice with increased macrophage uPA expression or nontransgenic controls (all apolipoprotein E-null [Apoe(-/-)]) was transplanted into 35-week-old Apoe(-/-) recipients, and innominate lesions and aortas were examined 8 to 13 weeks later. Donor macrophages accumulated in innominate lesions adjacent to plaque caps and in aortas, increasing uPA expression at both sites. Recipients of uPA-overexpressing macrophages had an increased prevalence of intraplaque hemorrhage (61% versus 13%; P=0.002) as well as increased lesion fibrin staining and fibrous cap disruption (P=0.06 for both). Transplantation of uPA-overexpressing macrophages increased aortic matrix metalloproteinase activity (40%; P=0.02). This increase was independent of matrix metalloproteinase-9. CONCLUSIONS: In advanced plaques of Apoe(-/-) mice, macrophage uPA overexpression causes intraplaque hemorrhage and fibrous cap disruption, features associated with human plaque rupture. uPA overexpression also increases vascular matrix metalloproteinase activity. These data provide a mechanism that connects macrophage uPA expression, matrix metalloproteinase activity, and plaque rupture features in mice. The data also suggest that elevated plaque plasminogen activator expression and plasminogen activation in humans may be causally linked to plaque rupture and cardiovascular events.
BACKGROUND: The mechanisms of atherosclerotic plaque rupture are poorly understood. Urokinase-type plasminogen activator (uPA) is expressed at elevated levels by macrophages in advanced human plaques. Patients with evidence of increased plasminogen activation have an elevated risk of major cardiovascular events. We used atheroscleroticmice to test the hypothesis that increased macrophage uPA expression in advanced plaques would cause histological features similar to those in ruptured human plaques. METHODS AND RESULTS: Bone marrow from transgenic mice with increased macrophage uPA expression or nontransgenic controls (all apolipoprotein E-null [Apoe(-/-)]) was transplanted into 35-week-old Apoe(-/-) recipients, and innominate lesions and aortas were examined 8 to 13 weeks later. Donor macrophages accumulated in innominate lesions adjacent to plaque caps and in aortas, increasing uPA expression at both sites. Recipients of uPA-overexpressing macrophages had an increased prevalence of intraplaque hemorrhage (61% versus 13%; P=0.002) as well as increased lesion fibrin staining and fibrous cap disruption (P=0.06 for both). Transplantation of uPA-overexpressing macrophages increased aortic matrix metalloproteinase activity (40%; P=0.02). This increase was independent of matrix metalloproteinase-9. CONCLUSIONS: In advanced plaques of Apoe(-/-) mice, macrophage uPA overexpression causes intraplaque hemorrhage and fibrous cap disruption, features associated with human plaque rupture. uPA overexpression also increases vascular matrix metalloproteinase activity. These data provide a mechanism that connects macrophage uPA expression, matrix metalloproteinase activity, and plaque rupture features in mice. The data also suggest that elevated plaque plasminogen activator expression and plasminogen activation in humans may be causally linked to plaque rupture and cardiovascular events.
Authors: M E Rosenfeld; P Polinsky; R Virmani; K Kauser; G Rubanyi; S M Schwartz Journal: Arterioscler Thromb Vasc Biol Date: 2000-12 Impact factor: 8.311
Authors: Marten Falkenberg; Clifford Tom; Mary Beth DeYoung; Shan Wen; Ruth Linnemann; David A Dichek Journal: Proc Natl Acad Sci U S A Date: 2002-07-29 Impact factor: 11.205
Authors: Aaron E Cozen; Hideaki Moriwaki; Michal Kremen; Mary Beth DeYoung; Helén L Dichek; Katherine I Slezicki; Stephen G Young; Murielle Véniant; David A Dichek Journal: Circulation Date: 2004-04-19 Impact factor: 29.690
Authors: Mariann Gyöngyösi; Dietmar Glogar; Franz Weidinger; Hans Domanovits; Anton Laggner; Johann Wojta; Gerlinde Zorn; Nelli Iordanova; Kurt Huber Journal: Am Heart J Date: 2004-01 Impact factor: 4.749
Authors: Veena Naik; Elizabeth M Leaf; Jie Hong Hu; Hsueh-Ying Yang; Ngoc B Nguyen; Cecilia M Giachelli; Mei Y Speer Journal: Cardiovasc Res Date: 2012-03-21 Impact factor: 10.787
Authors: Stephen D Farris; Jie Hong Hu; Ranjini Krishnan; Isaac Emery; Talyn Chu; Liang Du; Michal Kremen; Helén L Dichek; Elizabeth Gold; Stephen A Ramsey; David A Dichek Journal: J Biol Chem Date: 2011-05-02 Impact factor: 5.157
Authors: Jie Hong Hu; Phanith Touch; Jingwan Zhang; Hao Wei; Shihui Liu; Ida K Lund; Gunilla Høyer-Hansen; David A Dichek Journal: Cardiovasc Res Date: 2015-01-23 Impact factor: 10.787
Authors: Hao Chen; Donghang Zheng; Jeff Abbott; Liying Liu; Mee Y Bartee; Maureen Long; Jennifer Davids; Jennifer Williams; Heinz Feldmann; James Strong; Katrina R Grau; Scott Tibbetts; Colin Macaulay; Grant McFadden; Robert Thoburn; David A Lomas; Francis G Spinale; Herbert W Virgin; Alexandra Lucas Journal: Antimicrob Agents Chemother Date: 2013-06-17 Impact factor: 5.191